DaVita's CFO Says The Final Dialysis Rule's 3.5% Raise Fades After The First Quarter
CFO Joel Ackerman puts the net 2027 benefit at 1.5% to 2%, and says technology spending will keep growing.
DaVita's headline 3.5% Medicare rate increase for 2027 is mostly a first-quarter effect, Chief Financial Officer Joel Ackerman said on the company's third-quarter earnings call on Thursday, putting the net 2027 benefit at an estimated 1.5% to 2%.
A raise that shrinks after January
DaVita, which runs kidney dialysis centers and related kidney care businesses, got its first look at the final federal payment rule a day before the call. Ackerman stressed that 1.5% to 2% is an estimate, an improvement of somewhere north of 50 basis points (half a percentage point) over the prior proposal. Each 1% change in Medicare is worth about $30 million a year to the company, he said.
The rule works differently from past years, Ackerman said. Add-on payments for newly bundled drugs are now recalculated every quarter, not once a year, so the published figure applies only to the first quarter.
The fixed portion for large dialysis companies is 40 basis points, he said. The add-on component is 3.1% and he expects it to "come down significantly in Q2" and possibly fall further through the year. In his words, the year is "stronger in q1 a little bit weaker over the rest of the year."
Asked on behalf of analyst Justin Lake about that 3.1%, Ackerman said phosphate binders matched expectations and the increase is largely about a newly bundled drug, which the transcript renders as "FENCAST." He said DaVita has little visibility into industry utilization for the second half of 2026, so it cannot track what drives the quarterly reset.
Technology spending keeps climbing in 2027
On 2027, Ackerman told a Deutsche Bank analyst that volume growth should beat 2026 and pharmaceutical costs, led by binders, should fall. Commercial mix, with the loss of ACA exchange patients the big piece, will pull on revenue per treatment.
Technology is the exception to falling costs. "IT spend will not come down next year," he said, though growth should slow from the 20-plus percent pace of the last three or four years. Tech spending rose more than 20% in the third quarter, and CEO Javier Rodriguez said it ran above forecast this year, weighing on full-year results.
Full 2027 margin guidance is too early, Ackerman said. "We'll know more in February."
The quarter and the narrowed outlook
DaVita reported third-quarter adjusted operating income of $561 million, adjusted earnings per share of $3.82 and free cash flow of $276 million. It narrowed 2026 guidance to adjusted operating income of $2.175 billion to $2.25 billion and adjusted EPS of $14.30 to $15.20.
Integrated kidney care is now expected to produce at least $65 million of adjusted operating income this year, $25 million above prior guidance. Rodriguez said the higher IKC outlook is offset by higher U.S. dialysis costs, particularly technology.
Full-year free cash flow is still expected at $1 billion to $1.25 billion. DaVita's market value was $11.7 billion after Thursday's session.
DaVita's guidance for 2026 now sits in a narrower band, with the quarterly add-on reset the main swing factor Ackerman flagged for 2027.
Sources
- DaVita Non-GAAP EPS of $3.82 beats by $0.25, revenue of $3.57B beats by $50M (DVA:NYSE) | Seeking Alpha — seekingalpha.com
- DaVita HealthCare: Q3 Earnings Snapshot – WTOP News — wtop.com
- Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? — Yahoo Finance